Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Neuralstem

Sort by

Neuralstem: An Update on Its Pipeline and Supporting Clinical Trials (CUR, Neutral, $1.00)

Thursday, January 7, 2016 · 11:25 am

Read More

Neuralstem: My Analysis of Phase 1 and Phase 2 Results for NSI-566 Neural Stem Cells in ALS Indicates Encouraging Signals of Efficacy (CUR, Buy, $1.25)

Friday, October 16, 2015 · 11:04 am

Read More

Neuralstem: Initial Thoughts on Just Released Encouraging Phase 2 Data on the Use of NSI-566 Stem Cells to Treat ALS. Neuralstem Will Proceed to a Potentially Registrational Trial in 2016 (CUR, Buy, $1.50)

Tuesday, September 29, 2015 · 9:59 am

Read More

Neuralstem: The 2015 Decline in the Stock is in Contrast to Encouraging ALS Data and an Impressive Pipeline (CUR, Buy, $1.38)

Thursday, August 13, 2015 · 9:54 am

Read More

Neuralstem: A Closer Look at Encouraging Phase 2 Results for NSI-566 Neural Stem Cells in Treating ALS (CUR, Buy, $2.36)

Monday, March 16, 2015 · 2:34 pm

Read More

Neuralstem: Initial Take on Top Line Results of Phase 2 ALS Trial of NSI-566 Neural Stem Cells (CUR, Buy, $3.08)

Thursday, March 12, 2015 · 10:11 am

Read More

Neuralstem: When Will We See the Phase 2 Data for NSI-566 in ALS? (CUR, Buy, $3.75)

Tuesday, March 10, 2015 · 9:52 am

Read More

Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)

Tuesday, August 26, 2014 · 10:35 am

Read More

Neuralstem: Phase 1b Results for NSI-189 are Very Encouraging but It Is Early Days (CUR, Buy, $4.38, For paid subscribers)

Monday, June 23, 2014 · 11:58 am

Read More

Neuralstem: An In-Depth Look at NSI-189, A Novel Small Molecule Drug Being Studied in Major Depressive Disorder (CUR, Buy, $3.60, For Paid Subscribers)

Thursday, May 1, 2014 · 10:55 am

Read More

Neuralstem: Dr. Eva Feldmanís Latest Presentation on The Use of CURís Stem Cells in ALS (CUR, Buy, $4.04)

Friday, April 11, 2014 · 1:44 pm

Read More

Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)

Monday, March 17, 2014 · 2:21 pm

Read More

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Friday, February 14, 2014 · 4:28 pm

Read More

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

Wednesday, January 22, 2014 · 3:48 pm

Read More

Neuralstem: Sizing Up Potential Key Events of 2014 (CUR, $3.42)

Wednesday, January 8, 2014 · 11:12 am

Read More

Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)

Thursday, September 19, 2013 · 5:53 pm

Read More

Neuralstem: Anticipating More Efficacy Data from ALS Trial (CUR, $1.18)

Monday, May 6, 2013 · 11:30 am

Read More

Initiating Coverage of Neuralstem with a Buy (CUR, $0.92)

Monday, November 5, 2012 · 8:15 am

Read More

There are 18 reports on file.

« Back to Company Reports Index